Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

To follow the revision of the fourth edition of WHO classification and the recent progress on
the management of diffuse gliomas, the joint guideline committee of Chinese Glioma …

Grade II and III gliomas are generally slowly progressing brain cancers, many of which
eventually transform into more aggressive tumors. Despite recent findings of frequent …

Glioblastoma is an aggressive brain tumor that carries a poor prognosis. The tumor's
molecular and cellular landscapes are complex, and their relationships to histologic features …

Simple Summary Glioblastoma is the most common and aggressive malignant primary brain
cancer in adults. The prognosis remains poor following standard-of-care treatment with …

Background Inactivation of the tumor suppressor p53 is critical for pathogenesis of glioma, in
particular glioblastoma multiforme (GBM). MDM2, the main negative regulator of p53, binds …

Long noncoding RNAs (lncRNA) have emerged as essential players in cancer biology.
Using recent large-scale RNA-seq datasets, especially those from The Cancer Genome …

The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic
functions: it initiates and sustains neoplastic transformation when genetically altered …

Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with
limited therapeutic option and poorly understood mechanism. By studying the mutational …